Author

Hao‐Wei Wang

National Cancer InstituteORCID 0000-0002-5408-9253Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Nirali N. ShahiD· 2 shared Adila IzgutdinaiD· 1 shared Akul Naik· 1 shared Allison Barz LeahyiD· 1 shared Amit VermaiD· 1 shared Amrik S. KangiD· 1 shared Antonio ValeriiD· 1 shared Arun P. WiitaiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Nirali N. ShahORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies

Adila Izgutdina, Tasfia Rashid, William C. Temple, Sarah Aminov, Bonell Patiño-Escobar, Sujata B. Walunj, Huimin Geng, Hiroyuki Takamatsu, Daniel Gil-Alós, Amrik S. Kang, Emilio Ramos, Szu‐Ying Chen, Haley Johnson, Matthew A. Nix, Akul Naik, , Arun P. Wiita

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

Journal for ImmunoTherapy of Cancer · Dec 1, 2025Peer-reviewedImmunology

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia

Pablo Domizi, Jolanda Sarno, Astraea Jager, Milton J. Merchant, Kaithlen Zen Pacheco, Sean A. Yamada‐Hunter, Maria Caterina Rotiroti, Yuxuan Liu, Reema Baskar, Warren D. Reynolds, Brian J. Sworder, Bita Sahaf, Sean C. Bendall, Charles Grenfell Mullighan, Ash A. Alizadeh, , Kara Lynn Davis

This study identifies IKAROS as a factor associated with antigen escape in B-ALL, showing that low IKAROS levels lead to reduced B-cell antigen expression and resistance to CD19- and CD22-targeted therapies.

Nature Communications · Apr 23, 2025Peer-reviewedCancer Biology